InvestorsHub Logo
Followers 60
Posts 7866
Boards Moderated 0
Alias Born 05/18/2007

Re: kevindenver post# 399058

Thursday, 01/19/2023 3:01:17 PM

Thursday, January 19, 2023 3:01:17 PM

Post# of 466985
Rare diseases along with indication expansion based upon S1R and muscarinic receptors will be the focus on the research front.

I think Rett syndrome will be the first indication to market


News related to research front does not move the pps even though it is quite essential for long term growth and survival.

You are right about Rett Syndrome being the fist indication to make it to the market. (This indirectly implies that AD magic won't happen quickly enough; just like we waited on PDD after the initial euphoria).

However, there is still a lot of time for Rett to get approval. It may happen in 2023 or who knows in 2024, (given how Anavex operates, it is no walk in the park).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News